tbuckley/cabot-search huggingface dataset:
Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation
Authors: Vaishali Sanchorawala, Anthony C Shelton, Dina Brauneis, Karen Quillen, Nancy T Andrea, John Mark Sloan, David C Seldin
Journal: Blood (2012)
Subsequent treatment with APC8015F and its effect on survival in the control arm of phase III sipuleucel-t studies.
Authors: D. J. George, C. Nabhan, L. G. Gomella, J. B. Whitmore, M. W. Frohlich
Journal: Journal of Clinical Oncology (2011)

139 Background: Sipuleucel-T is an autologous cellular immunotherapy approved for metastatic castrate resistant prostate cancer. Methods: After disease progression, subjects in the control arms of 3 randomized controlled sipuleucel-T trials were offered 3 infusions of APC8015F, an autologous immunotherapy made from cells cryopreserved at the time of control generation. Results: Of 249 control subjects, 165 (66.3%) received APC8015F; the median time from randomization to first infusion was 5.2 months (range 1.8 to 33.1), median time from objective disease progression to first APC8015F infusion was 2.2 months (range 0.5 to 14.6), and 145 subjects (87.9%) received all 3 infusions. The frequency of infusional toxicities was increased following APC8015F relative to control infusion, but was slightly lower than following sipuleucel-T. APC8015F-treated subjects (n=155) had improved post-progression survival relative to untreated controls (n=61) (HR=0.52 [95%CI 0.37, 0.73] p=0.0001, log rank test, unadjusted Cox regression); however, APC8015F-treated subjects had more favorable prognostic features than untreated controls. A Cox regression analysis adjusting for baseline PSA and LDH demonstrated that APC8015F therapy remained a predictor of survival in control subjects (HR=0.56 [95%CI 0.40, 0.80]; p=0.001). A Cox regression model adjusting for age, PSA, LDH and post-randomization docetaxel use (yes/no), also showed a significant effect for salvage treatment among control subjects (HR=0.55 [95%CI 0.39, 0.78] p&lt;0.001). Examination of APC8015F product characteristics demonstrated that cumulative CD54 upregulation was associated with survival following first infusion in subjects who progressed and received APC8015F (p=0.03), consistent with previous reports of correlations between sipuleucel-T product parameters and overall survival. Conclusions: Although confounded with measured and unmeasured factors influencing outcome, these analyses suggest that post-progression treatment with APC8015F may have extended the survival of subjects in the control arms of these studies. [Table: see text]
Intraoperative open-cavity implant for APBI using HDR multicatheter brachytherapy for Japanese patients with breast cancer and their cosmetic outcomes.
Authors: K. Sato, H. Takayanagi, Y. Mizuno, T. Shimo, M. Kato
Journal: Journal of Clinical Oncology (2011)

e11550 Background: The efficacy of an accelerated partial breast irradiation (APBI) has been investigated compared with whole-breast irradiation (WBI). APBI starting just after surgery might give more benefit by intra-operative insertion of catheters. Although balloon catheter-based APBI is available in the US, it would not be adapted for Japanese women with small breast. When the applicators are implanted during operation for the tumor, APBI can start just after surgery. The aim of this study is an assessment of the efficacy and safety of APBI using intra-operative open-cavity implant (IOCI) technique. Methods: Patients (≥40yrs) with invasive breast cancer (≤3 cm) were enrolled. Before the lumpectomy, the insertion of applicators and delivery doses were simulated with CT. After the confirmation of the free margin and negative SNs for metastasis using frozen section analysis, applicators were inserted. Dose distribution analysis, using dose-volume histograms, was achieved based on a postoperative CT. APBI was started the same day of the operation. APBI therapy delivered 32 Gy in 8 fractions over 5-6 days with coverage of 2 cm tumor margins. Results: From October 2008 to Jan 2011, 107 women were enrolled (55.0 y/o, <40:10, sn+:19, for patients’ request). The mean number of applicators was 6.8 (2-15). The mean PTV was 36.7cm3 (6.5-137). All toxicities related to radiation therapy were mild. However, 7 patients had wound break due to infection. One patient developed ILBR and received second conservative surgery. Cosmetic outcomes were assessed using Harvard Breast Cosmesis Grading for 72/86 patients (>6 months after surgery), 61 patients (85%) could achieve excellent/good cosmetic results. Conclusions: Although this study is a small number of participants and short follow-up period, this convenient technique should be needed to establish clinical efficacy and safety.
Biogenesis and Exocytosis of Weibel-Palade Bodies Is Affected by Naturally Occurring Von Willebrand Disease Variants within the A1-A3 Domains of VWF
Authors: Dafna J Groeneveld, Jiong-Wei Wang, Marjon J Mourik, Richard J Dirven, Karine M Valentijn, Jan Voorberg, Pieter H. Reitsma, Jeroen C. J. Eikenboom
Journal: Blood (2012)
Effect of lenalidomide (LEN) on biochemical responses and clinical benefit (CB) as a single agent in chemotherapy-naive castration-resistant prostate cancer (CRPC).
Authors: Chadi Nabhan, Anand Patel, Dana Villines, Kathy Tolzien, Susan K. Kelby, Timothy M. Lestingi
Journal: Journal of Clinical Oncology (2012)

128 Background: LEN has anti-angiogenesis and immunomodulatory properties making it ideal to investigate in CRPC. We report on a phase II study investigating LEN in chemotherapy-naïve CRPC patients (pts) Methods: Eligible pts received LEN at 25 mg daily on days 1 – 21 every 28-days until progression. Daily aspirin or coumadin were required. Responses were assessed every 2 cycles. Toxicity was assessed every cycle. Primary end point: The CB of LEN [Sum of complete response (CR), partial response (PR) and stable disease (SD)]. Secondary end points: Toxicity, time to radiographic and PSA progression (TTP and TTP-PSA), time to next treatment (TTNT), overall survival (OS), and LEN’s impact on quality of life (QOL). Results: 31 pts were enrolled; 27 response-evaluable (1 withdrew consent, 3 off per choice after adverse events). Median age is 74 (range 58-89) with 24 (77%) having Gleason ≥ 7 disease. Median PSA is 66 (2.1-918.6). Six pts (19%) had liver/lung involvement. Fourteen pts (51%) showed biochemical response with 4 (15%) having &gt;50% PSA drop. TTP-PSA is 4 months (2-11). No radiographic responses seen but 17 pts had SD for a median of 4 months (2-16) (CB=55%). Median number of LEN cycles was 3 (2-15). With a median follow-up of 18 months (5-38), 17 patients (55%) remain alive; median OS of 18 months. Grade 3/4 hematologic toxicities were most common (neutropenia 41%, leukopenia 12%, anemia 9%, thrombocytopenia 9%). Other grade 3/4 toxicities: venothromboembolism, atrial fibrillation, and dehydration (6% each). Serious adverse events (SAEs) were witnessed in 10 pts (32%) with only 1 (3%, rash) definitely related to LEN. Others were not related or possibly related. Of 27 pts, 7 (26%) had a dose reduction and 2 (7%) required two dose reductions. Dose reductions occurred after cycle 3. QOL scales suggested no adverse impact. Median TTNT is 2 months (9 pts received chemotherapy, 10 pts went onto studies, 3 pts received hormonal therapies, 4 pts received radiation, 3 pts had no therapy yet, and 2 pts remain on LEN). Conclusions: LEN is active as monotherapy in CRPC. Biochemical responses are witnessed and clinical benefit is observed. Myelosuppression is the most common toxicity.
A Retrospective Single Center Comparison of Cyclophosphamide Plus G-CSF Versus G-CSF Alone for Peripheral Blood Stem Cell (PBSC) Mobilisation Following First Line Therapy in Patients with Multiple Myeloma
Authors: Richard S Whitmill, David J Lewis, David John Sutton, Jahanzeb Khawaja, Georgina Mayer, Shankaranarayana Paneesha, Emmanouil Nikolousis, Bhuvan Kishore
Journal: Blood (2015)
Long-Term Surveillance of Allogeneic and Autologous Hemopoietic Stem Cell Transplant Recipients Affected by Primary Occult Hepatitis B Virus Infection
Authors: Roberto Cairoli, Luigi Mancini, Giambattista Bertani, Maria Luisa De Angelis, Nadia Vantaggiato, Clara Cesana, Valentina Mancini, Enrica Morra, Maria Lisa Ribero, Alessandro Tagger
Journal: Blood (2010)
Prognostic role of triple-negative subtype in breast cancer patients with brain metastases.
Authors: A. Mathew, M. Q. Rosenzweig, A. Brufsky
Journal: Journal of Clinical Oncology (2011)

36 Background: Metastatic breast cancer (MBC) patients with brain metastases (BM) have a poorer prognosis compared to patients with metastases to sites such as bone or other visceral organs. The role of breast cancer subtypes such as triple negative (TN) status and its relationship with other known prognostic factors have not been well delineated in the context of metastatic disease to the brain. We conducted a retrospective single institution cohort study of MBC patients with BM to evaluate the association between TN subtype and overall survival from the diagnosis of BM. Methods: Baseline demographic and tumor specific data including ER, PR and HER2 status were collected on newly diagnosed MBC patients between January 1998 and December 2009. Overall survival was determined from the date of diagnosis of BM. Survival analyses were performed using the Kaplan-Meier method and Cox proportional-hazards model. Results: Data were available on 186 MBC patients with BM, of whom 156 died during a median follow-up of 10.2 months from the diagnosis of BM; median age was 47.9 years. 91% of patients were Caucasian; 25.3% had triple negative disease. Median survival from the period of diagnosis of BM in patients with triple negative disease was 7 months (Interquartile range, IQR: 3–13) as compared to 11 months (IQR: 5–22) in patients who were HER2-positive or ER/PR-positive. Multivariate analysis found a higher risk of death after BM for TN disease subtype, with a hazard ratio for death of 2.89 (95% confidence interval: 1.89–4.44; p&lt;0.001), when adjusted for variables such as age and stage at initial diagnosis of breast cancer, race, the number of metastatic sites, and the use of metastatic chemotherapy. The administration of metastatic chemotherapy had a significant survival benefit in the analyses, with a hazard ratio for death of 0.52 (95% CI: 0.27–0.99; p=0.048). Conclusions: This retrospective cohort study in MBC patients with BM provides evidence for a greater risk of death in those with TN disease as compared to HER2-positive or ER/PR-positive subtypes even after adjusting for other prognostic factors.
Tolerance of docetaxel: Is obesity a risk factor for toxicity? A pilot study.
Authors: D. Parent, A. Rallet, N. Jovenin, G. Yazbek, H. Cure, J. Rey
Journal: Journal of Clinical Oncology (2011)

248 Background: Few data are available in the literature regarding chemotherapy dosage adjustment in obese patients. Docetaxel is a lipophilic substance, highly bound to albumin; obesity might result in an accumulation and may lead to a higher rate of toxicity. The objective of this study was to assess the tolerance to docetaxel in obese and non obese patients, according to their body mass index (BMI). Methods: A retrospective study was performed. Patients were divided according to their BMI, considering a limit of 30 kg/m 2 . All patients received docetaxel (100 mg/m 2 ) as a part of adjuvant chemotherapy for breast carcinoma. Toxicity of docetaxel such as neutropenia, hand-foot syndrome (HFS), mucositis, and neuropathy were assessed in both groups. The included patients received docetaxel alone or in association with trastuzumab or bevacizumab. Qualitative data analysis was performed using Fisher's exact test. Quantitative data were studied using the Student test. Results: Among the 49 patients, 18 (37%) presented with a BMI greater than 30 kg/m 2 . The median age was 53 years in the group BMI greater than 30 and 55 years in the group BMI less than 30 (p = 0.9383). The median value for albumin was 75 g/L (59-86 g/L) in the BMI greater than 30 and 71 g/L (56-79 g/L) in the BMI less than 30 (p = 0.122). Toxicity in both groups is shown in the table below. No neuropathy was observed. Conclusions: Obese patients (BMI &gt; 30 kg/m 2 ) presented with more toxicities (p = 0.013). Hypoalbuminemia did not represent a risk factor for toxicity in this study. Obesity is a risk factor for toxicity in patients treated with docetaxel. Dosage calculation according to body surface area is not suitable for these patients. Toxicity in the group BMI &lt; 30 seems to demonstrate greater susceptibility to the molecule for these patients. Further studies will try to identify the different mechanisms of toxicity of docetaxel involved obese patients, including the interaction between docetaxel and fats. Measures have also to be taken to obtain a favorable effectiveness/toxicity balance in obese patients. [Table: see text]
Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long Term Follow-up Data.
Authors: Vikram Mathews, Biju George, Kavitha M Lakshmi, Auro Viswabandya, Ezhilarasi Chendamarai, Poonkuzhali Balasubramanian, Ramachandran Shaji, Vivi Srivastava, Alok Srivastava, Mammen Chandy
Journal: Blood (2009)
Cangrelor Use Since FDA Approval
Authors: Muthiah Vaduganathan, Arman Qamar, Abhayjit Singh, Ramkumar V. Venkateswaran, Paul M. Szumita, Kevin J. Croce, Laura Mauri, Jane A. Leopold, Pinak B. Shah, Piotr Sobieszczyk, David P. Faxon, Deepak L. Bhatt
Journal: Journal of the American College of Cardiology (2016)
Ethnic disparity of treatment initiation in women diagnosed with breast cancer.
Authors: M. Omaira, M. Mozayen, R. Mushtaq, K. Katato
Journal: Journal of Clinical Oncology (2011)

189 Background: Despite the major advances in early detection and treatment of breast cancer (BC), African American women, continued to have a higher mortality rates than Caucasians. Many studies have failed to identify a key factor to explain racial disparities in breast cancer outcome. These disparities persist even after controlling for insurance and socioeconomic settings. Data about delays in treatment initiation are limited and inconclusive. We intend to compare the time from diagnosis to the initiation of treatment between African American and Caucasian women diagnosed with BC in a single community-based cancer registry. Methods: Women aged 18 to 64 years with breast cancer were identified, between 1993 and 2009, using data from the Tumor Registry at Hurley Medical Center in Flint, Michigan. Patient’s characteristics obtained include age at diagnosis, race, stage, date of diagnosis, and date of treatment initiation. All patients were previously insured or became insured after diagnosis. Time from diagnosis to the initiation of treatment was calculated in days and compared between African American and Caucasian women using t-test. Results: A total of 1016 patients have been identified with diagnosis of BC. 23 patients were excluded due to missing data. 993 patients were analyzed. African Americans were 355 (36%), Caucasians 617 (62%), and other ethnicities 21 (2%). Mean age at diagnosis was (48.9) for African Americans versus (51.45) for Caucasians (p = 0.005). African American women were more likely to present with advanced stage (III, IV) than Caucasians (18% versus 12%, p = 0.009). African American women had significant delay in the treatment initiation of BC compared to Caucasians (31.11 versus 21.52 days, p &lt; 0.0001). Conclusions: African American women were diagnosed with breast cancer at younger age and more advanced disease than Caucasians. African American women experienced significant delay in the initiation of therapy after diagnosis compared to Caucasians. However, the impact of an average delay of 10 days in treatment on overall survival is unknown. The exact explanation of this disparity is yet to be determined.
G-CSF Receptor Lysine Residues Are Involved in Lysosomal Degradation and Attenuation of G-CSF Signaling Via Distinct Effector Mechanisms.
Authors: Lambertus H. Aarts, Mahban Irandoust, Onno Roovers, Marijke Valkhof, Stefan J. Erkeland, Ivo P. Touw
Journal: Blood (2005)
Immune Reconstitution Following the Use of Targeted Radiotherapy for Reduced Intensity Conditioning in Allogeneic Stem Cell Transplantation: A Single Centre Experience
Authors: Amy Publicover, Deborah S. Richardson, Efrem Eren, Kate Hill, Elizabeth Hodges, Carol Hurlock, Sara Main, Nikki McKeag, Joan Newman, Theresa Schneider, Kim H. Orchard
Journal: Blood (2012)
Risk of recurrence and economic burden of early-stage, triple-negative breast cancer in a U.S.-managed care setting.
Authors: L. Xie, W. Wei, H. J. Henk, O. Baser
Journal: Journal of Clinical Oncology (2011)

e11563 Background: Triple-negative breast cancer (TNBC), characterized by absence of ER and PR expression and lack of HER2 overexpression, is a high-grade BC with an aggressive clinical course. Evidence of differences in recurrence and associated economic burden between TNBC and non-TNBC is lacking. Objective: To compare recurrence rate, healthcare utilization, cost between early-stage TNBC and non-TNBC. Methods: This retrospective study used the Impact Intelligence Oncology Management system linked with 1999-2009 managed care administrative claims and social security administration mortality data. Staging, ER, PR, and HER2 status were obtained at diagnosis; local/distant recurrence was identified from medical claims. Stage I-III TNBC and non-TNBC patients were followed from diagnosis to recurrence, disenrollment, or end of observation period. Risk-adjusted recurrence rate, healthcare utilization, and costs during the follow-up period were compared. Results: 1967 patients with stage I-III BC (403 with TNBC) were included. During the follow-up period, 289 (14.7%) had local/distant recurrence. TNBC patients were younger (54 vs 56 years, P<0.0001) and more likely to experience recurrence (21.6% vs 12.9%, P<0.0001; adjusted HR=2.11, P<0.0001) vs non-TNBC. In terms of adjusted annual healthcare utilization and costs, patients with TNBC had significantly higher numbers of hospitalizations (all-cause: 1.20 vs 0.90, P=0.001; cancer-related: 0.62 vs 0.47, P=0.004), hospitalization days (all-cause: 8.8 vs 4.97, P<0.0001; cancer-related: 4.2 vs 2.6, P=0.004), emergency room visits (all-cause: 1.45 vs 0.95, P=0.009; cancer-related: 0.62 vs 0.39, P=0.026). TNBC patients had significantly higher inpatient costs (all-cause: $9,154 vs $5,501; cancer-related: $5,632 vs $2,869; P<0.0001 for both), emergency room costs (all-cause: $303 vs $182, P=0.003; cancer-related: $240 vs $138, P=0.012), inpatient costs to payers (all-cause: $7,347 vs $4,241; cancer-related: $4,471 vs $2,438, P<0.0001 for both). Conclusions: Using actual patient records, this real-world study demonstrates that TNBC is associated with a higher recurrence rate, increased healthcare utilization and costs vs non-TNBC.
Impact of reconstruction on satisfaction with contralateral prophylactic mastectomy.
Authors: J. C. Boughey, T. L. Hoskin, L. C. Hartmann, J. L. Johnson, S. R. Jacobson, A. C. Degnim, M. H. Frost
Journal: Journal of Clinical Oncology (2011)

240 Background: Contralateral prophylactic mastectomy (CPM) is increasingly chosen by patients with breast cancer. Satisfaction after CPM is high. However, decreased satisfaction has been associated with reoperation after reconstruction. This study’s aim was to examine the adverse aspects patients attribute to reconstruction and the subsequent effect on psychosocial consequences and satisfaction with CPM. Methods: 487 unilateral breast cancer patients with a family history of breast cancer who underwent CPM between 1960 and 1993 were mailed a questionnaire evaluating QOL and satisfaction with CPM. Results: Of 269 respondents, 210 (78%) underwent reconstruction and 59 (22%) did not. Mean age at CPM was 46 and 50 years respectively (p=0.01). Mean follow-up was 20.2 years. Reconstruction was immediate in 96%, 98% with implants and 2% with tissue flap. Reconstruction was associated with lower satisfaction with CPM (p=0.03), but still only 7% (vs 2% in those without reconstruction) said they were dissatisfied. Most (83%) of those with reconstruction said they would choose reconstruction again while 7% were unsure and 10% said they would not. In those who did not undergo reconstruction, 18% said they would choose reconstruction if able to make the choice again while 5% were unsure and 77% said they still would not. 95 patients (45%) of those that underwent reconstruction required one or more reoperations for complications. Those with reoperation reported poorer responses for satisfaction with CPM (p=0.04), choice to have CPM again (p=0.008), and choice to have reconstruction again (p=0.004) when compared to patients with reconstruction and no reoperation. Those with and without reconstruction did not differ significantly with respect to femininity, sexual relationships or emotional stability, but those without reconstruction reported significantly poorer effects related to self esteem (p=0.04) and body appearance (p=0.002). Conclusions: In patients who undergo CPM, many years after surgery satisfaction with CPM is higher in those choosing not to have reconstruction than those with reconstruction although it was high in both groups. Reoperation is common after reconstruction and is associated with lower satisfaction.
Phase II study of a polyethoxylated castor oil–free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Authors: J. Lee, S. Park, H. Lim, J. Kwon, G. Kim, C. Song, J. Hong, C. Kim, H. Ahn, J. Ahn
Journal: Journal of Clinical Oncology (2011)

272 Background: Paclitaxel-loaded polymeric micelle (Genexol-PM; G-PM) is a novel polyethoxylated castor oil (Cremophor EL [CrEL])-free formulation of paclitaxel. This multicenter phase II study was designed to evaluate the efficacy and safety of the G-PM monotherapy for the treatment of gemcitabine- and cisplatin-refractory advanced urothelial cancer. Methods: Patients with advanced urothelial cancer received G-PM 240 mg/m 2 intravenously over 3 hours every 3 weeks without premedication as salvage chemotherapy after failure to gemcitabine and cisplatin combination chemotherapy. Intrapatient dose escalation of G-PM to 300 mg/m 2 was carried out from the second cycle if the prespecified toxicities were not observed after the first cycle. Results: Thirty-seven patients were enrolled in this study. Platinum-free interval was less than 6 months in 72% of patients and 64% of patients were categorized into intermediate or poor prognostic group. Overall response rate was 19% including one complete response. When response occurs it is long lasting with a median response duration of 7.8 months (range 1.5∼19.3+). The median progression-free survival was 2.7 months (95% CI, 09-4.6) with a median overall survival of 5.7 months (95% CI, 3.1-8.3). The most common major grade 3-4 non-hematologic toxicity was peripheral neuropathy (sensory type 5.6% and motor type 8.3%) followed by infection (5.6%). Grade 3 or worse hematologic toxicities were observed in only one patient. Conclusions: G-PM showed modest activity with favorable toxicity profiles when used as salvage therapy after gemcitabine-cisplatin failure in advanced urothelial cancer. No significant financial relationships to disclose.
Myocardial and Hepatic Iron Overload and Cardiac Function In Sickle/Thalassemia Patients Of Italian Origin
Authors: Antonella Meloni, Giovan Battista Ruffo, Daniele De Marchi, Antonio Cardinale, Anna Pietrapertosa, Elena Facchini, Patrizia Toia, Lucia De Franceschi, Vincenzo Positano, Massimo Lombardi, Alessia Pepe
Journal: Blood (2013)
Delayed Platelet Engraftment and Outcome of Stem Cell Transplant for Multiple Myeloma: Possible Microenvironment Effect?.
Authors: Shaji Kumar, Angela Dispenzieri, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, David Dingli, Mark R. Litzow, S. Vincent Rajkumar, Morie A. Gertz
Journal: Blood (2007)